Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Telaprevir | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Telaprevir | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Telaprevir | hsa00220 | Arginine biosynthesis | 1.21E-02 | 1 | P15104 | GLUL | More | | Telaprevir | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | Telaprevir | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Telaprevir | hsa00310 | Lysine degradation | 8.45E-03 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Telaprevir | hsa00500 | Starch and sucrose metabolism | 4.45E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Telaprevir | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Telaprevir | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Telaprevir | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | Telaprevir | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Telaprevir | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Telaprevir | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Telaprevir | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Telaprevir | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Telaprevir | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | | Telaprevir | hsa01230 | Biosynthesis of amino acids | 4.06E-03 | 4 | P60891, P05089, P15104, P37837 | PRPS1, ARG1, GLUL, TALDO1 | More | | Telaprevir | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Telaprevir | hsa03013 | RNA transport | 4.09E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Telaprevir | hsa03015 | mRNA surveillance pathway | 4.36E-02 | 3 | Q9BZI7, O43809, Q9H307 | UPF3B, NUDT21, PNN | More | | Telaprevir | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | Telaprevir | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | | Telaprevir | hsa04060 | Cytokine-cytokine receptor interaction | 2.05E-02 | 11 | P27930, P14778, P26842, Q13651, P25024, P25025, Q9UBD3, P47992, P09341, P18510, P01730 | IL1R2, IL1R1, CD27, IL10RA, CXCR1, CXCR2, XCL2, XCL1, CXCL1, IL1RN, CD4 | More | | Telaprevir | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.04E-02 | 6 | P09341, P25024, P25025, P47992, Q9UBD3, Q13651 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, IL10RA | More | | Telaprevir | hsa04062 | Chemokine signaling pathway | 9.25E-05 | 11 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | Telaprevir | hsa04064 | NF-kappa B signaling pathway | 8.34E-07 | 18 | P10415, Q13489, P25963, P51617, O00463, Q13546, P14778, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q13315, P24522, P09341, Q9UNE0 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, RIPK1, IL1R1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, ATM, GADD45A, CXCL1, EDAR | More | | Telaprevir | hsa04071 | Sphingolipid signaling pathway | 9.39E-03 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Telaprevir | hsa04080 | Neuroactive ligand-receptor interaction | 5.67E-03 | 9 | P08311, Q15722, P21453, Q9H228, O00398, Q01726, P41968, P21462, P21730 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, MC1R, MC3R, FPR1, C5AR1 | More | | Telaprevir | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Telaprevir | hsa04141 | Protein processing in endoplasmic reticulum | 2.78E-02 | 3 | P07384, O95487, O95816 | CAPN1, SEC24B, BAG2 | More | | Telaprevir | hsa04142 | Lysosome | 2.64E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Telaprevir | hsa04145 | Phagosome | 7.50E-03 | 10 | Q15080, P14598, Q13509, Q13488, Q99437, P05164, O60603, P35443, P13765, P25774 | NCF4, NCF1, TUBB3, TCIRG1, ATP6V0B, MPO, TLR2, THBS4, HLA-DOB, CTSS | More | | Telaprevir | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Telaprevir | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Telaprevir | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Telaprevir | hsa04360 | Axon guidance | 1.50E-02 | 3 | P20827, P23528, Q06124 | EFNA1, CFL1, PTPN11 | More | | Telaprevir | hsa04371 | Apelin signaling pathway | 1.94E-03 | 5 | P63218, Q14344, Q13485, P84022, Q16566 | GNG5, GNA13, SMAD4, SMAD3, CAMK4 | More | | Telaprevir | hsa04530 | Tight junction | 2.08E-02 | 3 | P63261, Q9Y478, Q92974 | ACTG1, PRKAB1, ARHGEF2 | More | | Telaprevir | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Telaprevir | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | Telaprevir | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | Telaprevir | hsa04613 | Neutrophil extracellular trap formation | 1.30E-03 | 13 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P20160, P08311, P49913, P21730, P21462 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1 | More | | Telaprevir | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Telaprevir | hsa04621 | NOD-like receptor signaling pathway | 7.18E-04 | 13 | Q14643, P01568, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q13546, Q05823, P01375, P49913, P12838 | ITPR1, IFNA21, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RIPK1, RNASEL, TNF, CAMP, DEFA4 | More | | Telaprevir | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Telaprevir | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Telaprevir | hsa04640 | Hematopoietic cell lineage | 3.31E-03 | 9 | P13612, P14778, P27930, P11836, P07766, P09693, P01732, P01730, P13765 | ITGA4, IL1R1, IL1R2, MS4A1, CD3E, CD3G, CD8A, CD4, HLA-DOB | More | | Telaprevir | hsa04650 | Natural killer cell mediated cytotoxicity | 8.81E-06 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.807 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.799 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.733 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.888 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.712 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Telaprevir | hsa04658 | Th1 and Th2 cell differentiation | 1.64E-06 | 11 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Telaprevir | hsa04659 | Th17 cell differentiation | 2.83E-05 | 11 | Q04759, Q16539, P01730, P06239, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Telaprevir | hsa04660 | T cell receptor signaling pathway | 7.21E-08 | 16 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08246 | ELA2 | Neutrophil elastase | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | -0.854 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.727 | P08246 | ELA2 | Neutrophil elastase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.724 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.709 | P08246 | ELA2 | Neutrophil elastase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.782 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.759 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.75 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.798 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Telaprevir | hsa04662 | B cell receptor signaling pathway | 2.57E-02 | 5 | P49841, P60033, P07948, P21854, Q8N149 | GSK3B, CD81, LYN, CD72, LILRA2 | More | | Telaprevir | hsa04668 | TNF signaling pathway | 2.59E-02 | 7 | P01375, O00463, Q13489, P25963, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, NFKBIA, BCL3, TRAF1, MMP9 | More | | Telaprevir | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Telaprevir | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Telaprevir | hsa04714 | Thermogenesis | 1.25E-02 | 3 | P15336, P63261, Q9Y478 | ATF2, ACTG1, PRKAB1 | More | | Telaprevir | hsa04724 | Glutamatergic synapse | 1.84E-02 | 3 | O15399, P63218, Q9NSB8 | GRIN2D, GNG5, HOMER2 | More | | Telaprevir | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Telaprevir | hsa04730 | Long-term depression | 1.63E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Telaprevir | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Telaprevir | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Telaprevir | hsa04920 | Adipocytokine signaling pathway | 4.71E-03 | 6 | P25963, Q06124, P33121, Q9Y478, Q04759, P01375 | NFKBIA, PTPN11, ACSL1, PRKAB1, PRKCQ, TNF | More | | Telaprevir | hsa04970 | Salivary secretion | 4.49E-02 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Telaprevir | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Telaprevir | hsa05010 | Alzheimer disease | 2.57E-02 | 5 | O15399, Q9NZJ5, Q13564, Q71U36, P21796 | GRIN2D, EIF2AK3, APPBP1, TUBA1A, VDAC1 | More | | Telaprevir | hsa05014 | Amyotrophic lateral sclerosis | 1.56E-02 | 6 | O15399, Q9NZJ5, Q71U36, P21796, P43243, P84103 | GRIN2D, EIF2AK3, TUBA1A, VDAC1, MATR3, SFRS3 | More | | Telaprevir | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | Telaprevir | hsa05020 | Prion disease | 4.79E-02 | 4 | O15399, Q9NZJ5, P21796, Q71U36 | GRIN2D, EIF2AK3, VDAC1, TUBA1A | More | | Telaprevir | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Telaprevir | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.83E-04 | 5 | Q16539, P09341, P25024, P25025, P07948 | MAPK14, CXCL1, CXCR1, CXCR2, LYN | More | | Telaprevir | hsa05130 | Pathogenic Escherichia coli infection | 9.80E-03 | 4 | Q92974, P63261, Q06124, O95487 | ARHGEF2, ACTG1, PTPN11, SEC24B | More | | Telaprevir | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Telaprevir | hsa05132 | Salmonella infection | 2.05E-03 | 14 | P51617, P25963, P01375, Q9UJU2, Q13546, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, O60282, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, RIPK1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Telaprevir | hsa05133 | Pertussis | 2.24E-02 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Telaprevir | hsa05135 | Yersinia infection | 2.14E-03 | 7 | P13612, P06239, Q16539, P01375, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, TNF, GSK3B, CD4, CD8A | More | | Telaprevir | hsa05140 | Leishmaniasis | 1.18E-02 | 7 | P14598, P13765, O60603, P25963, P01375, P51617, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, TNF, IRAK1, NCF4 | More | | Telaprevir | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Telaprevir | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Telaprevir | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Telaprevir | hsa05152 | Tuberculosis | 9.13E-03 | 11 | Q13488, Q99437, P48382, O60603, P01375, P10415, P13765, P25774, P49913, Q9UDY8, P51617 | TCIRG1, ATP6V0B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CTSS, CAMP, MALT1, IRAK1 | More | | Telaprevir | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Telaprevir | hsa05163 | Human cytomegalovirus infection | 4.44E-04 | 10 | P01375, P63218, P50151, P49841, P14778, Q13651, P25025, Q16539, O00463, P30101 | TNF, GNG5, GNG10, GSK3B, IL1R1, IL10RA, CXCR2, MAPK14, TRAF5, PDIA3 | More | | Telaprevir | hsa05166 | Human T-cell leukemia virus 1 infection | 3.68E-02 | 6 | P27824, P30279, P21796, P84022, Q13485, Q13042 | CANX, CCND2, VDAC1, SMAD3, SMAD4, CDC16 | More | | Telaprevir | hsa05169 | Epstein-Barr virus infection | 1.68E-03 | 12 | P13765, Q13547, O00463, Q16539, P07948, P30101, Q13761, P24522, P29728, P07766, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, LYN, PDIA3, RUNX3, GADD45A, OAS2, CD3E, CD3G, CD247 | More | | Telaprevir | hsa05170 | Human immunodeficiency virus 1 infection | 1.56E-04 | 21 | P63218, P50151, P01375, P17252, O00463, P30101, Q14643, P01730, Q16539, P51617, P25963, O60603, Q13315, O95067, P07766, P09693, P20963, P10415, Q13619, Q93034, Q9Y6Q5 | GNG5, GNG10, TNF, PRKCA, TRAF5, PDIA3, ITPR1, CD4, MAPK14, IRAK1, NFKBIA, TLR2, ATM, CCNB2, CD3E, CD3G, CD247, BCL2, CUL4A, CUL5, AP1M2 | More | | Telaprevir | hsa05202 | Transcriptional misregulation in cancer | 1.51E-04 | 14 | Q12778, Q15532, Q13315, P14780, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Telaprevir | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | | Telaprevir | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | | Telaprevir | hsa05222 | Small cell lung cancer | 2.79E-02 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Telaprevir | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.92E-04 | 8 | O95267, P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | Telaprevir | hsa05310 | Asthma | 1.70E-03 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | Telaprevir | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Telaprevir | hsa05321 | Inflammatory bowel disease | 1.28E-02 | 5 | O60603, P01375, P13765, Q14765, P23771 | TLR2, TNF, HLA-DOB, STAT4, GATA3 | More | | Telaprevir | hsa05322 | Systemic lupus erythematosus | 4.20E-02 | 7 | P08246, P08311, P01375, P10747, P13765, Q6FI13, P05455 | ELA2, CTSG, TNF, CD28, HLA-DOB, H2AC18; H2AC19, SSB | More | | Telaprevir | hsa05330 | Allograft rejection | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Telaprevir | hsa05332 | Graft-versus-host disease | 9.30E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Telaprevir | hsa05340 | Primary immunodeficiency | 3.99E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Telaprevir | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | Telaprevir | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Telaprevir | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |